Literature DB >> 20938485

Molecular phylogeny of edge hill virus supports its position in the yellow Fever virus group and identifies a new genetic variant.

Joanne Macdonald1, Michael Poidinger, John S Mackenzie, Richard C Russell, Stephen Doggett, Annette K Broom, Debra Phillips, Joseph Potamski, Geoff Gard, Peter Whelan, Richard Weir, Paul R Young, Debra Gendle, Sheryl Maher, Ross T Barnard, Roy A Hall.   

Abstract

Edge Hill virus (EHV) is a mosquito-borne flavivirus isolated throughout Australia during mosquito surveillance programs. While not posing an immediate threat to the human population, EHV is a taxonomically interesting flavivirus since it remains the only member of the yellow fever virus (YFV) sub-group to be detected within Australia. Here we present both an antigenic and genetic investigation of collected isolates, and confirm taxonomic classification of the virus within the YFV-group. Isolates were not clustered based on geographical origin or time of isolation, suggesting that minimal genetic evolution of EHV has occurred over geographic distance or time within the EHV cluster. However, two isolates showed significant differences in antigenic reactivity patterns, and had a much larger divergence from the EHV prototype (19% nucleotide and 6% amino acid divergence), indicating a distinct subtype or variant within the EHV subgroup.

Entities:  

Keywords:  EHV; Edge Hill virus; flavivirus; yellow fever virus

Year:  2010        PMID: 20938485      PMCID: PMC2901633          DOI: 10.4137/ebo.s4966

Source DB:  PubMed          Journal:  Evol Bioinform Online        ISSN: 1176-9343            Impact factor:   1.625


Edge Hill virus (EHV) is a mosquito-borne flavivirus that has been isolated during mosquito-surveillance programs conducted in the Northern Territory, Queensland, Western Australia, and New South Wales.1–3 While the Flavivirus genus is known to harbor serious global pathogens such as yellow fever virus (YFV), West Nile virus (WNV) and the dengue viruses (DENV),4 EHV has only once been implicated in human disease. In this instance, virus symptoms included myalgia, arthralgia and fatigue.5 Generally, EHV sero-conversion by humans is rare,6 indicating the virus is of low risk to the human population. Indeed EHV has mainly been associated with marsupial infections, since antibodies reactive to EHV have been detected in wallabies, kangaroos and bandicoots.6,7 Taxonomically, EHV is a unique flavivirus since it remains the only member of the YFV sub-group to be detected within Australia. Adding to the interest, historically the classification of EHV was briefly contentious. The virus was originally classified within the Uganda S antigenic complex via cross-neutralization tests using polyclonal antisera,8,9 but later RNA hybridization studies suggested EHV might share up to 70% sequence homology with DENV-2 virus,10 which belongs to a different antigenic clade.8,9 Moreover, monoclonal antibody 1B7, previously thought to be dengue specific, was found to cross-react with EHV in an ELISA,10 suggesting an antigenic similarity between these viruses. Antigenic homology to DENV-2 could have serious implications for DENV detection and subsequent dengue hemorrhagic fever epidemiology within Australia.11 However, subsequent partial nucleotide sequencing of EHV did not confirm a relationship with DENV-2.12,13 Rather, sequencing confirmed a homology with other members of the YFV group, and EHV is classified by the ICTV within this group.14 Geographically, the closest near-neighbour of EHV is Sepik virus (SEPV), which has been isolated in Papua New Guinea (PNG) but not in Australia.15,16 Reasons for the apparent geographic delineation of these viruses, and the notable absence of YFV in both countries, presumably involve availability of mosquito vectors and host organisms. Additionally, the prevalence of one strain could be exclusionary to other related strains. Since the original isolation of EHV in a suburb of Cairns in 1961, we and others have isolated the virus in Western Australia, Queensland, New South Wales, and the Northern Territory (Table 1). Here we present both an antigenic and genetic investigation of these isolates. For antigenic analysis, monoclonal antibodies to EHV were raised using either the C281 or the PH235 isolate, and for historical purposes we also tested antibodies raised to DENV-2, along with some reference DENV monoclonals17 (Table 2). Monoclonal antibody (mAb) binding patterns of isolates were determined by inoculation of isolates onto confluent 96-well monolayers of C6/36 cells, incubation for up to 7 days, and subsequent assay by tissue culture enzyme immunoassay.18 The four antibodies raised to C281 recognized all EHV isolates: 3D11 was found to be EHV-specific, while 6A9 also recognized YFV, 7C6 cross-reacted with SEPV, and 8G2 reacted with both SEPV and Banzi virus (BANV). Of the antibodies produced to PH235, only 6F7 recognized all the EHV isolates. The remaining antibodies (3B11, 3G1, 5D3, and 7C3) failed to recognize isolates P1553 and V366. Interestingly, with the exception of 6F7, which also recognized SEPV, the monoclonal antibodies produced to PH235 did not react with other flaviviruses used in this study. Finally, monoclonal antibodies raised to DENV-2 were also tested against EHV and a panel of flaviviruses. These antibodies were found to recognize only viruses within the dengue group, except for 1D1, which recognized all flaviviruses tested. Five reference dengue monoclonal antibodies (15F3, 3H5, 5D4, 1H10 and 2H2) also failed to react with EHV.
Table 1.

Details of Edge Hill virus isolates used in this study.1

StrainPlace of isolationDate of isolationSource
C281*Edge Hill (Cairns) QLD1961Cx. annulirostris
P1553Marble Bar (Pilbara region-WA)16/3/94Cx. ENM#92
GU0068Normanton, QLD13/4/2000Ae. normanensis
PH235Newman (Pilbara region-WA)18–21/3/79Ae. bancroftianus
SW42148Leschenault Inlet (South-West Region-WA)15/1/96Ae. camptorhynchus
K22005Broome (Kimberley region-WA)28/3/96Ae. vigilax
V366Darwin, NT5/1/83Ae. vigilax
19542unknownbefore 1976unknown
22144Batemans Bay (NSW)17/1/95Ae. vigilax
22441Batemans Bay (NSW)17/1/95Ae. vigilax
22897Batemans Bay (NSW)23/1/95Ae. vigilax
22905Batemans Bay (NSW)23/1/95Ae. vigilax
22969Batemans Bay (NSW)23/1/95Ae. vigilax
23056Batemans Bay (NSW)6/2/95Ae. vigilax
23060Batemans Bay (NSW)6/2/95Ae. vigilax
23072Batemans Bay (NSW)6/2/95Ae. vigilax
23462Batemans Bay (NSW)14/2/95Ae. vigilax
23543Batemans Bay (NSW)20/2/95Ae. vigilax
23562Batemans Bay (NSW)20/2/95Ae. vigilax
23703Batemans Bay (NSW)14/2/95Ae. vigilax
24045Tathra (NSW)7/3/95Ae. vigilax
24880Ballina (NSW)10/4/95Ae. procax
25716Maclean (NSW)5/4/95Ae. vigilax
26314Boggabilla (NSW)11/3/96Cx. annulirostris
33029Port Stephens (NSW)19/2/96Ae. vigilax

Prototype strain.

Table 2.

Binding patterns of monoclonal antibodies as determined by ELISA when tested with EHV isolates and a selection of flaviviruses.

VirusesmAbs prepared to EHV strain C281
mAbs prepared to EHV strain PH235
3D11a6A9a7C6a8G2b3B11b3G1c5D3c7C3c6F7b

EHV C281*+++++++++
EHV PH235*+++++++++
EHV 26314++++www+
EHV P1553+++++
EHV V366+++++
BANV+
YFV+
SEPV+++
DENV 1
DENV 2
DENV 3
DENV 4
MVEVNT
KOKV**NT

mAbs prepared to DENV 2
mAbs prepared to DENV 1, 2, 3 or 417
1D1b2C5-2b3A9b3B2-1b15F3c3H5b5D4c1H10c2H2a

EHV C281*+
EHV PH235*+
EHV 26314+
EHV P1553+
EHV V366+
BANV+
YFV+
DENV 1+++++
DENV 2++++++
DENV 3++++
DENV 4+++
MVEV+NTNTNT
KOKV**+NTNTNT

Legend: +, positive; −, negative; w, weak reaction; NT, not tested.

C281, PH235 and other EHV isolates (except 26314, P1553 and V366) had identical reaction patterns.

Viral protein reactivity of some mAbs was determined by Western blot under non-reducing conditions:

Antibodies 3B11, 6A9, 7C6, and 2H2 bind to prM.

Antibodies 8G2, 6F7, 1D1, 2C5-2, 3A9, 3B2-1 and 3H5 bind to E.

Viral protein recognized by 3G1, 5D3, 7C3, 15F3, 5D4 and 1H10 could not be determined by Western blot.

Kokobera virus (KOKV).

Our monoclonal antibody analysis confirmed that EHV is antigenically similar to YFV, BANV and SEPV, and lacks antigenic similarity to DENV-2. Interestingly, the monoclonal antibodies created using the PH235-based immunogen had a different reaction pattern compared to the antibodies induced by a C281-based immunogen, despite antigenic similarity between both isolates. This difference in antibody panel reactivity is probably due to differences in mouse immunization procedures, since the PH235 antibodies were created from immunizations with extracts of infected suckling mouse brain (see Supplementary Material, SM), whereas the C281-derived immunogens comprised purified but inactivated virus cultured in Vero cells (D. Phillips, personal communication). The most interesting observation from the antigenic studies was the distinct reaction pattern of isolates P1553 and V366, from Western Australia and the Northern Territory respectively. Testing against the panel of C281-derived antibodies clearly indicated these isolates were antigenically more similar to the EHV prototype than our representative YFV, BANV and SEPV isolates, however they showed a distinct antigenic pattern from the EHV prototype when tested against the PH235-derived antibody panel. These data indicate that P1553 and V366 represent a second antigenic subtype of EHV. We subsequently performed a genetic investigation of EHV isolates via nucleotide sequencing. Several consensus primers were tested for RT-PCR amplification of RNA extracted from EHV infected cell culture supernatant. Only one primer pair (FG1 and FG2)19 successfully amplified any of the EHV isolates—yielding an approximately 1kb portion within the viral NS5 gene. The lack of amplification from the other primer pairs tested suggests significant divergence of EHV from other more characterized flaviviruses. Indeed, the recent report of the full genomic sequence of a single strain of EHV, published after the completion of the present study, has yielded additional information on the evolution of EHV and other members of the YFV group, and will be useful for the design of improved flavivirus-group consensus primers throughout the genome.20 Nucleotide (Fig. 1) and amino acid (SM) sequence analysis of the amplified products indicated homology within the YFV group for all EHV isolates as expected, supported by 100% of bootstrap replicates. Moreover, despite geographic disparity, most EHV isolates had a very high degree of genetic similarity, with less than 1% nucleotide (nt) divergence. Clustering based on geographic origin or time of isolation was not observed, indicating that genetic evolution within the EHV cluster has been minimal over geographic distance and time. However, isolates P1553 and V366 showed a much larger divergence from the EHV C281 prototype (19% nt and 6% amino acid divergence). This degree of divergence is larger than the genetic distance between Kunjin and West Nile viruses (11% nt and 1% amino acid divergence), which are currently classified as separate subtypes within the WNV virus species.14 However the divergence is distinctly smaller than the divergence between DENV-1 and DENV-3 (72% nt), Murray valley encephalitis virus (MVEV) and Alfuy virus (ALFV) (74% nt), and BANV and Uganda S virus (UGSV) (76% nt), indicating classification as a separate virus is not warranted. Combined with our antigenic data, these results clearly indicate that isolates P1553 and V366 represent a distinct subtype or variant of EHV.
Figure 1.

Phylogenic analysis of EHV nucleotide sequences. EHV and other mosquito-borne flavivirus nucleotide sequences (660 nucleotides) of the NS5 gene were aligned using Clustal W.23 Phylogenetic analysis was performed with the PHYLIP analysis package24 using the following parameters: DNA distances were obtained from the Kimura 2-parameter algorithm, phylogenetic relationships determined with the neighbour-joining algorithm, and statistical significance of clusters calculated by bootstrapping 100 replicates and subsequent determination of consensus trees. Bootstrap (B) values are shown in the grey italics, and percent nucleotide similarity (nt) is shown in blue. EHV strains are shown in red, whereas EHV variants are shown in green. Scale bar indicates the distance length of 10 percent divergence.

With only 2 representative strains, the origin and divergence of the EHV variant cannot be determined, but full-length sequence analysis could provide valuable information. Current data appears to preclude a recombination event, and the geographic location of the variant isolates indicates that they most likely co-exist with the prototype strain. Such a coexistence of two EHV subtypes within the YFV group suggests that strain exclusion is perhaps an unlikely scenario for the absence of other YFV group viruses in Australia. Recently Australia has seen the emergence of both JEV21 and a new KOKV-like virus,22 both of which are suspected to have been introduced from PNG. The determination of a second subtype of EHV, and detections of Sepik virus in PNG,15 indicate a serious possibility of the introduction of further YFV-group viruses into Australia. We recommend that virulence studies in mouse models of both Sepik and the EHV variant be performed to assess risks of disease in man.
  20 in total

1.  Multiple outbreaks of dengue serotype 2 in north Queensland, 2003/04.

Authors:  Jeffrey N Hanna; Scott A Ritchie; Ann R Richards; Carmel T Taylor; Alyssa T Pyke; Brian L Montgomery; John P Piispanen; Anna K Morgan; Jan L Humphreys
Journal:  Aust N Z J Public Health       Date:  2006-06       Impact factor: 2.939

2.  Characterization of Sepik and Entebbe bat viruses closely related to yellow fever virus.

Authors:  Goro Kuno; Gwong-Jen J Chang
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

3.  Phylogeny of the genus Flavivirus.

Authors:  G Kuno; G J Chang; K R Tsuchiya; N Karabatsos; C B Cropp
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera.

Authors:  C H Calisher; N Karabatsos; J M Dalrymple; R E Shope; J S Porterfield; E G Westaway; W E Brandt
Journal:  J Gen Virol       Date:  1989-01       Impact factor: 3.891

5.  Short report: the first isolation of Japanese encephalitis virus from mosquitoes collected from mainland Australia.

Authors:  Andrew F Van Den Hurk; Brian L Montgomery; Judith A Northill; Ina L Smith; Paul Zborowski; Scott A Ritchie; John S Mackenzie; Greg A Smith
Journal:  Am J Trop Med Hyg       Date:  2006-07       Impact factor: 2.345

6.  Possible clinical infection with Edge Hill virus.

Authors:  J G Aaskov; D A Phillips; M A Wiemers
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jul-Aug       Impact factor: 2.184

7.  Rapid identification of flaviviruses based on conserved NS5 gene sequences.

Authors:  L Fulop; A D Barrett; R Phillpotts; K Martin; D Leslie; R W Titball
Journal:  J Virol Methods       Date:  1993-10       Impact factor: 2.014

8.  Arbovirus infections of humans in New South Wales. Seroepidemiology of the flavivirus group of togaviruses.

Authors:  R A Hawkes; C R Boughton; H M Naim; J Wild; B Chapman
Journal:  Med J Aust       Date:  1985 Dec 9-23       Impact factor: 7.738

9.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

Authors:  E A Henchal; M K Gentry; J M McCown; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

10.  Genomics and evolution of Aedes-borne flaviviruses.

Authors:  Gilda Grard; Grégory Moureau; Rémi N Charrel; Edward C Holmes; Ernest A Gould; Xavier de Lamballerie
Journal:  J Gen Virol       Date:  2009-09-09       Impact factor: 3.891

View more
  12 in total

1.  Detection of Entebbe Bat Virus After 54 Years.

Authors:  Rebekah C Kading; Robert Kityo; Teddie Nakayiki; Jeremy Ledermann; Mary B Crabtree; Julius Lutwama; Barry R Miller
Journal:  Am J Trop Med Hyg       Date:  2015-06-22       Impact factor: 2.345

Review 2.  Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Authors:  Kathryn A Hanley; Thomas P Monath; Scott C Weaver; Shannan L Rossi; Rebecca L Richman; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2013-03-20       Impact factor: 3.342

3.  The Impact of Prior Flavivirus Infections on the Development of Type 2 Diabetes Among the Indigenous Australians.

Authors:  Alanna Sorenson; Leigh Owens; Marie Caltabiano; Yvonne Cadet-James; Roy Hall; Brenda Govan; Paula Clancy
Journal:  Am J Trop Med Hyg       Date:  2016-03-21       Impact factor: 2.345

4.  The RNA Secondary Structure Analysis Reveals Potential for Emergence of Pathogenic Flaviviruses.

Authors:  Bibhudutta Mishra; Raviprasad Aduri
Journal:  Food Environ Virol       Date:  2021-10-25       Impact factor: 2.778

5.  Serological evidence of infection with dengue and Zika viruses in horses on French Pacific Islands.

Authors:  Cécile Beck; Isabelle Leparc-Goffart; Denise Desoutter; Estelle Debergé; Hervé Bichet; Steeve Lowenski; Marine Dumarest; Gaelle Gonzalez; Camille Migné; Jessica Vanhomwegen; Stéphan Zientara; Benoit Durand; Sylvie Lecollinet
Journal:  PLoS Negl Trop Dis       Date:  2019-02-07

6.  Natural exposure of horses to mosquito-borne flaviviruses in south-east Queensland, Australia.

Authors:  Natalie A Prow; Cindy S E Tan; Wenqi Wang; Jody Hobson-Peters; Lisa Kidd; Anita Barton; John Wright; Roy A Hall; Helle Bielefeldt-Ohmann
Journal:  Int J Environ Res Public Health       Date:  2013-09-17       Impact factor: 3.390

7.  Neglected Australian Arboviruses and Undifferentiated Febrile Illness: Addressing Public Health Challenges Arising From the 'Developing Northern Australia' Government Policy.

Authors:  Narayan Gyawali; Richard S Bradbury; John G Aaskov; Andrew W Taylor-Robinson
Journal:  Front Microbiol       Date:  2017-11-07       Impact factor: 5.640

8.  Characterization of Fitzroy River Virus and Serologic Evidence of Human and Animal Infection.

Authors:  Cheryl A Johansen; Simon H Williams; Lorna F Melville; Jay Nicholson; Roy A Hall; Helle Bielefeldt-Ohmann; Natalie A Prow; Glenys R Chidlow; Shani Wong; Rohini Sinha; David T Williams; W Ian Lipkin; David W Smith
Journal:  Emerg Infect Dis       Date:  2017-08       Impact factor: 6.883

Review 9.  What Does the Future Hold for Yellow Fever Virus? (I).

Authors:  Raphaëlle Klitting; Ernest A Gould; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-06-08       Impact factor: 4.096

10.  The recently identified flavivirus Bamaga virus is transmitted horizontally by Culex mosquitoes and interferes with West Nile virus replication in vitro and transmission in vivo.

Authors:  Agathe M G Colmant; Sonja Hall-Mendelin; Scott A Ritchie; Helle Bielefeldt-Ohmann; Jessica J Harrison; Natalee D Newton; Caitlin A O'Brien; Chris Cazier; Cheryl A Johansen; Jody Hobson-Peters; Roy A Hall; Andrew F van den Hurk
Journal:  PLoS Negl Trop Dis       Date:  2018-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.